Ludwig Enterprises, Inc. reported its financial results for the third quarter and the nine months ended September 30, 2025, revealing a net loss of $1,159,135, a significant improvement compared to a net loss of $2,649,983 for the same period in 2024. The company did not generate any revenue during the current quarter or the nine-month period, a decline from $207 and $217 in revenue reported for the same periods in the previous year. Total operating expenses increased to $1,481,907 for the nine months ended September 30, 2025, up from $1,021,684 in 2024, primarily due to higher general and administrative costs and increased research and development expenditures.
The company's balance sheet as of September 30, 2025, showed total assets of $261,594, compared to $197,556 at the end of 2024. Current liabilities rose significantly to $3,572,502 from $2,575,701, largely driven by increased accounts payable and accrued liabilities, which reached $1,310,515. The stockholders' deficit also widened to $3,310,908 from $2,378,145, reflecting ongoing financial challenges. The company had cash on hand of only $3,317, indicating a critical liquidity position.
In terms of strategic developments, Ludwig Enterprises has focused on enhancing its research and development capabilities, with R&D expenses increasing to $230,608 for the nine months ended September 30, 2025, compared to $113,662 in the prior year. The company is actively seeking to launch new products utilizing mRNA technology aimed at addressing inflammation-related diseases. However, the company has acknowledged that it requires approximately $10 million in funding to support its operational and product development plans, with no assurance of securing such capital.
Operationally, Ludwig Enterprises has not reported any significant customer growth or product adoption metrics, as it has yet to generate revenue from its planned product offerings. The company has also undergone organizational changes, including the issuance of common stock for services, which totaled 1,057,000 shares for marketing services and 1,000,000 shares for research and development costs during the nine months ended September 30, 2025. The total number of shares outstanding increased to 162,569,807 as of November 5, 2025.
Looking ahead, Ludwig Enterprises has expressed intentions to execute its business operations more fully and explore strategic acquisitions in the healthcare technology sector. However, the company has raised substantial doubt about its ability to continue as a going concern, given its current financial position and the need for additional capital to sustain operations. The management's outlook remains cautious, emphasizing the uncertainty surrounding future funding and operational viability.
About LUDWIG ENTERPRISES, INC.
Ludwig Enterprises, Inc. develops genomic and mRNA-based health diagnostics focused on early detection of inflammation-related chronic diseases such as cancer, heart disease, and autoimmune disorders. Utilizing proprietary genetic biomarkers, machine learning AI, and saliva or blood samples, the company aims to provide personalized, preventative healthcare tools and diagnostic tests. Its business model includes developing laboratory-developed tests (LDTs), consumer screening kits, and conducting clinical research to improve disease management and treatment outcomes.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.